Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07750990 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)

StatusNot Yet Recruiting
PhasePhase 2
SponsorShionogi
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 31, 2026 to Nov 2, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 1 of 10 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Shionogi
45 trials monitored
See 2 trials at risk
The primary purpose of this study is to evaluate the long-term safety and tolerability profile of S-606001 in participants with LOPD. Participants who completed other S-606001 studies (for example, NCT07123155), including participants in a S-606001 study whose allocated arm was terminated by the sponsor and who are willing to participate in this study, will be enrolled globally.
Trial Details
NCT Number NCT07750990
Lead Sponsor Shionogi
Conditions
(from sponsor)		 Pompe Disease
Related terms Glycogen Storage Disease, Glycogen Storage Disease Type II, Rare Diseases
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov